Pyridoxine-Dependent Epilepsy as a Cause of Neonatal Seizures

Area of Science:

• Neurology
• Pediatrics
• Metabolic Disorders

Background:

• Neonatal seizures represent a significant clinical challenge, often necessitating emergency department visits.
• Early identification and management of inborn errors of metabolism are critical for preventing adverse developmental outcomes in infants.
• Pyridoxine-dependent epilepsy is a rare metabolic disorder presenting with refractory seizures in neonates.

Observation:

• A 9-day-old infant presented with seizures that were resistant to multiple anticonvulsant therapies.
• The infant was diagnosed with pyridoxine-dependent epilepsy, a condition requiring specific treatment.

Findings:

• Pyridoxine-dependent epilepsy is a treatable cause of refractory neonatal seizures.
• A trial of pyridoxine is a key diagnostic and therapeutic step in managing such cases.
• Pyridoxine administration can precipitate apnea and central nervous system depression, requiring careful monitoring and airway management.

Implications:

• This case highlights the importance of considering metabolic etiologies in neonatal seizures.
• Prompt recognition and treatment of pyridoxine-dependent epilepsy can significantly improve neurodevelopmental trajectories.
• Clinicians must be prepared for potential adverse effects of pyridoxine, including respiratory compromise, during treatment.